EC Number   |
Application |
Reference |
|---|
   3.4.22.B71 | medicine |
in bladder cancer cells, SENP2 inhibits MMP13 expression through deSUMOylation of TBL1/TBLR1, which inhibits nuclear translocation of beta-catenin |
755408 |
| 3.4.22.B71 | medicine |
muscle enzyme SENP2 can be a therapeutic target for the treatment of obesity-linked metabolic disorders |
731703 |
| 3.4.22.B71 | medicine |
SENP2 expression is significantly downregulated in clinical osteosarcoma tissues compared with adjacent normal samples. Ectopic expression of SENP2 results in the suppression of proliferation, migration and invasion in osteosarcoma cells, whereas SENP2 knockdown has the opposite effect. SENP2 is associated with the proteaxadsome-dependent ubiquitination and degradation of SRY-box-9 (SOX9). SOX9 silencing impairs SENP2-depletion-induced accelerated cell growth and migration |
753521 |
| 3.4.22.B71 | medicine |
SENP2 is frequently downregulated in bladder cancer, especially in metastatic bladder cancer. SENP2 downregulation is associated with more aggressive phenotypes and poor patient outcomes. SENP2 suppresses bladder cancer cell invasion in vitro and tumor metastasis in vivo, acts as a tumor suppressor gene in bladder cancer |
754706 |
